Skip to main content
. 2019 Oct 16;20(20):5128. doi: 10.3390/ijms20205128

Figure 2.

Figure 2

Correlations between the fasting serum gastrin levels (FSG) and the gastric enterochromaffin-like cells (ECL) cell proliferative index in ZES patients from two NIH studies. (A,B) show data from patients with sporadic ZES (n = 106) whereas (C) shows data from a study of patients (n = 57) with MEN1/ZES. All patients had multiple gastric biopsies and the proliferative ECL index was calculated from the degree of ECL changes in all biopsies and correlated with the FSG level. In (A) all 106 sporadic disease patients were included (90 active, 16 cured) and in (B), only patients with FSG levels <5-fold increased were included, which are levels overlapping with those seen in nonZES patients taking chronic PPIs. (C) shows the data from the 57 patients with MEN1/ZES. In all cases, there is a highly significant correlation of the FSG levels with the degree of ECL cell proliferative change. In (B), the data shows there is no threshold for gastrin’s ability to stimulate ECL cell proliferative effects as was proposed in the past. Figures are drawn from the data in [25,61].